Physician profile
Victoria Borovsky
NPI 1932130481
$8,461.89
in general payments reported to CMS, 2019-2025
51 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $497 · 2021: $1,504 · 2022: $1,414 · 2023: $1,273 · 2024: $1,424 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,808.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $738.35 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $668.20 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $654.60 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Abbvie INC. | $508.88 | 2020-2025 | Linzess, Viberzi, Qulipta |
| Janssen Pharmaceuticals, INC | $490.11 | 2019-2025 | Invega Sustenna, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $394.98 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $384.42 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $382.51 | 2021-2025 | |
| Lilly USA, LLC | $367.25 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $366.77 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.66 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amarin Pharma, INC. | $272.47 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $263.48 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $241.95 | 2019-2022 | |
| Pfizer INC. | $210.94 | 2019-2024 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Borovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.